Infection due to acyclovir resistant herpes simplex virus in patients undergoing allogeneic hematopoietic stem cell transplantation.
D000208:Acute Disease; D000212:Acyclovir / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D000293:Adolescent; D019943:Amino Acid Substitution; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002648:Child; D000077404:Cidofovir; D003062:Codon / Q000235:genetics; D003596:Cytosine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004252:DNA Mutational Analysis; D024882:Drug Resistance, Viral; D005260:Female; D017245:Foscarnet / Q000494:pharmacology / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000209:etiology / Q000401:mortality; D006561:Herpes Simplex / Q000188:drug therapy / Q000821:virology*; D006801:Humans; D016867:Immunocompromised Host; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000628:therapy; D007951:Leukemia, Myeloid / Q000150:complications / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000628:therapy; D008297:Male; D020125:Mutation, Missense; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000494:pharmacology / Q000627:therapeutic use; D017354:Point Mutation; D016879:Salvage Therapy; D018139:Simplexvirus / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics / Q000254:growth & development / Q000302:isolation & purification; D013937:Thymidine Kinase / Q000235:genetics; D014184:Transplantation, Homologous / Q000009:adverse effects; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology; D014764:Viral Proteins / Q000235:genetics; D014775:Virus Activation